公开(公告)号：US20070021332A1

公开(公告)日：2007-01-25

申请号：US10544035

申请日：2004-01-30

申请人： Miriam Tendler ,  Naftale Katz ,  Andrew Simpson ,  Isaias Raw ,  Paulo Ho ,  Celso Ramos

发明人： Miriam Tendler ,  Naftale Katz ,  Andrew Simpson ,  Isaias Raw ,  Paulo Ho ,  Celso Ramos

IPC分类号： A61K38/17 ,  C07K14/435 ,  G01N33/569

CPC分类号： C07K14/43559 ,  A61K38/00 ,  A61K39/00 ,  G01N33/56905

摘要： The primary objective of the present invention is the development of new mutant forms of the Sm14 protein, for producing a greater production volume. The recombinant proteins here obtained were capable of providing protection against schistosome and fasciola infection. The level of protection of Sm14 recombinant proteins obtained in the present invention was similar to that reached in the parasite saline extract. The mutant proteins of the present invention have reached approximately 100% of renaturation after the heating at 80° C., different from wild forms of the Sm14 protein. Moreover, after storage for 2 months at 4° C., mutant proteins have shown smaller β-structure loss than wild forms that have shown formation with random structure, as demonstrated by the circular dichroism analysis, indicating the success of mutations.

摘要翻译： 本发明的主要目的是开发新的突变形式的Sm14蛋白，用于产生更大的产量。 这里获得的重组蛋白能够提供针对血吸虫病和fasciola感染的保护。 在本发明中获得的Sm14重组蛋白的保护水平与寄生盐水提取物中达到的相似。 本发明的突变型蛋白质在80℃加热后与Sm14蛋白的野生型不同，达到约100％的复性。 此外，在4℃下保存2个月后，突变蛋白质显示比野生形式更小的β-结构损失，其显示出随机结构的形成，如通过圆二色性分析所证实的，表明突变的成功。